Email not displaying correctly? View it in your browser
Forward to a colleague | Sign up to BNF eNews
BNF BNF for Children Medicines Complete
April 2017 Share this issue Facebook LinkedIn Twitter
 
I Welcome
Welcome to the April BNF eNewsletter.
Seven new drug monographs have been added to the BNF in the last month, including - pegaspargase, asparaginase, sufentanil, ferric maltol, ceftolozane with tazobactam and, dexamethasone with ciprofloxacin. We have also updated the dose for lithium citrate [Li-liquid®].

This issue includes updated guidance on the management of erectile dysfunction, Crohn's disease, ulcerative colitis and new guidance on the management of early sepsis. We have also updated MHRA advice on hyoscine butylbromide injection and the risk of serious adverse events in patients with underlying cardiac disease. You will also find NICE technology appraisals for ibrutinib, pegaspargase, pembrolizumab and pomalidomide.

See also our BNF case study on the drug treatment of multiple sclerosis.
Kind regards,
BNF Team
I In this issue
Significant changes More >  
News More >  
How to purchase BNF More >  
Price reminder More >  
Drug safety update More >  
Feedback More >  
I Significant
changes
This month's changes to the clinical content of these publications are described in two parts:

BNF and BNFC update should be read by all users
BNF update should be read by all users of the BNF
BNF 73 - BNFC 2016-2017
BNF Update
Sufentanil: new drug monograph
For further information, see sufentanil.
Ceftolozane with tazobactam: new drug monograph
For further information, see ceftolozane with tazobactam.
Ferric maltol: new drug monograph
For further information, see ferric maltol.
Dose changes
Lithium Citrate [Li-liquid®]
For further information, see lithium citrate [Li-liquid®].
NICE technology appraisal update:
NICE technology appraisals that have been added to the BNF this month include:
Pegaspargase for treating acute lymphoblastic leukaemia
Pembrolizumab for treating PD-L 1-positive non-small-cell lung cancer after chemotherapy
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Other changes
To review other changes in the BNF, click on changes.
BNF BNF for Children Update
Hyoscine butylbromide injection: risk of serious adverse effects in patients with underlying cardiac disease (MHRA advice)
For further information, see hyoscine butylbromide.
Pegaspargase: new drug monograph
For further information, see pegaspargase.
Asparaginase: new drug monograph
For further information, see asparaginase.
Dexamethasone with ciprofloxacin: new drug monograph
For further information, see dexamethasone with ciprofloxacin.
I News
BNF Case study: The treatment of multiple sclerosis
Our BNF case study can help to improve your knowledge of the treatment of multiple sclerosis.
Reminder - help from CPPE with BNF 73
An interactive PDF e-learning programme from the Centre for Pharmacy Postgraduate Education (CPPE) will help you familiarise yourself with recommendations in BNF 73. It comprises 10 practical case studies, and can be accessed here.
BNF 72
I How to purchase BNF
Purchase Print copies
Purchase print copies
To order the March 2017 edition, visit the Pharmaceutical Press website.
More
Purchase a print subscription
Purchase a print subscription and save money
A print subscription is the best way to ensure access to the latest copy of BNF as soon as it publishes.
More
BNF online
BNF online
Outside the UK, content is available via a subscription to MedicinesComplete.
Email us
BNF eBook
BNF eBook
BNF is also available as a PDF eBook.
More
I Monthly price update reminder
Prices of all branded medicinal products in the BNF and BNFC are now updated monthly. Prices of generic preparations of medicinal products are updated every 2-4 months, to coincide with print editions of BNF and BNF for Children. The BNF team keep price information up to date using data sourced from the NHS dictionary of medicines and devices (dm+d).
Drug Safety Update
Drug Safety Update is a monthly newsletter from
the MHRA and Commission on Human Medicine.
Please follow this link to review this month's Drug Safety Update.
I Feedback on our eNewsletter
Please let us know if there are any issues that you'd like us to address in our eNewsletters. We welcome your feedback. If you have any comments or suggestions, please let us know at marketing@rpharms.com.
Subscribe to this eNewsletter here
I Related Products
Medicines Complete BNF Pharmaceutical Press
BNF
Copyright © 2017 BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. All rights reserved. Terms of use.
BNF for Children
Copyright © 2017 BMJ Publishing Group Ltd, the Royal Pharmaceutical Society of Great Britain and RCPCH Publications. All rights reserved. Terms of use.
If you do not wish to receive such mailings in the future please click here to unsubscribe.
Pharmaceutical Press, 66-68 East Smithfield, London, E1W 1AW, United Kingdom.